EMEA-001318-PIP01-12-M03

Key facts

Invented name
Relenza
Active substance
Zanamivir
Therapeutic area
Infectious diseases
Decision number
P/0415/2019
PIP number
EMEA-001318-PIP01-12-M03
Pharmaceutical form(s)
  • Inhalation powder, pre-dispensed
  • Solution for infusion
Condition(s) / indication(s)
  • Prevention of influenza
  • Treatment of influenza
Route(s) of administration
  • Inhalation use
  • Intravenous use
Contact for public enquiries
GlaxoSmithKline Trading Services Limited

Tel. +44 (0)20 8990 3650
E-mail: eu.paediatric-plans@gsk.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating